Waterfront Wealth Inc. Buys Shares of 18,518 Lantheus Holdings, Inc. $LNTH

Waterfront Wealth Inc. purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,518 shares of the medical equipment provider’s stock, valued at approximately $950,000.

Other institutional investors have also modified their holdings of the company. American Assets Inc. acquired a new position in shares of Lantheus in the 3rd quarter valued at approximately $872,000. Axim Planning & Wealth bought a new position in Lantheus in the third quarter valued at approximately $249,000. Gallacher Capital Management LLC lifted its stake in Lantheus by 228.9% in the third quarter. Gallacher Capital Management LLC now owns 13,388 shares of the medical equipment provider’s stock valued at $687,000 after buying an additional 9,317 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the period. Finally, Ashton Thomas Private Wealth LLC increased its position in shares of Lantheus by 68.1% during the third quarter. Ashton Thomas Private Wealth LLC now owns 21,312 shares of the medical equipment provider’s stock worth $1,093,000 after acquiring an additional 8,632 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on LNTH shares. Mizuho boosted their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial lifted their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Trading Up 0.0%

Shares of NASDAQ:LNTH opened at $64.89 on Monday. The company’s 50-day moving average price is $65.59 and its two-hundred day moving average price is $59.54. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock has a market capitalization of $4.30 billion, a PE ratio of 27.26 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same quarter in the previous year, the business earned $1.70 earnings per share. Lantheus’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.